VTRS · Earnings call · 2026Q2T · Full report
Regulatory Approval Milestones
Viatris Inc · 2026-08-06 · Importance 41 · Surprise 60 · In source text
Viatris received U.S. approval for Gwyn Lo, a once-weekly low-dose estrogen transdermal contraceptive patch, and expects to launch it later this year. Fast-acting meloxicam remains under FDA review with anticipated approval near year-end; management highlighted rapid absorption, opioid-sparing potential and an acute-pain market of approximately 80 million patients annually, with potential peak sales of up to $500 million. In Japan, Phase III Nefecon results were positive and a Japanese filing is targeted by the end of 2026, while pitolisant applications for narcolepsy and obstructive sleep apnea are in final review. Phase III programs for cenerimod and selatogrel remain on track for first-half 2027 readouts, and the company has secured 70 generic approvals in the first half toward more than 100 for the year, including 11 U.S. complex-injectable approvals over the past two years.
Key facts
- Viatris received U.S. regulatory approval for Gwyn Lo last week (prior to the call) ahead of its PDUFA date and expects to launch later in 2026
- Viatris expects FDA approval for fast-acting meloxicam toward the end of the year at the time of PDUFA
- In Japan, Viatris reported positive top line Phase III results for Nefecon and is targeting submission of a new drug application in Japan by the end of 2026
- Pitolisant applications for excessive daytime sleepiness associated with OSA and narcolepsy remain on track and are in final stages of review with anticipated regulatory decisions in the second half of 2026
- Phase III programs for selatogrel and cenerimod remain on track with important readouts expected in 2027 (first half)
- Viatris expects to achieve more than 100 new product approvals in 2026 with 70 approvals already secured in the first half
- Labeling negotiations for fast-acting meloxicam (including opioid-sparing language) expected to start in October-November 2026
- Fast-acting meloxicam NDA review is progressing and Viatris is approaching the mid-cycle point of the FDA review
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Viatris received U.S. regulatory approval for Gwyn Lo last week (prior to the call) ahead of its PDUFA date and expects to launch later in… |
| revenue | positive | probable | — | Viatris expects FDA approval for fast-acting meloxicam toward the end of the year at the time of PDUFA |
| revenue | positive | probable | — | In Japan, Viatris reported positive top line Phase III results for Nefecon and is targeting submission of a new drug application in Japan… |
| revenue | positive | probable | — | Pitolisant applications for excessive daytime sleepiness associated with OSA and narcolepsy remain on track and are in final stages of… |
| revenue | positive | probable | — | Phase III programs for selatogrel and cenerimod remain on track with important readouts expected in 2027 (first half) |
| revenue | positive | probable | — | Viatris expects to achieve more than 100 new product approvals in 2026 with 70 approvals already secured in the first half |